Neurosteroids for the pharmacotherapy of depression and other neuropsychiatric disorders: a review of clinical evidence

Postpartum (perinatal) depression (PPD) and treatment-resistant depression are prevalent affective disorders characterized by poor responsiveness to conventional antidepressant therapy. The family of neurosteroids (neuroactive steroids) comprises a number of endogenous molecules produced in the central and peripheral nervous systems, as well as their synthetic analogues, which are being investigated as promising therapeutic candidates. The primary mechanism of action of neurosteroids is based on the regulation of neuronal excitability through allosteric modulation of synaptic and extrasynaptic γ-aminobutyric acid receptors, predominantly the A subtype. Weak positive allosteric modulation of N-methyl-D-aspartate glutamate receptors and agonism at σ1-receptors further enhance the antidepressant effect and also account for the procognitive and neuroprotective properties observed in some neurosteroids. One of the most important advantages of neurosteroids as antidepressants is their rapid onset of action, which may be observed after the first administration. Zuranolone, available as oral capsules, has been approved in the United States and the European Union for the treatment of PPD in patients aged 18 years and older. In a number of clinical trials, zuranolone has demonstrated efficacy in major depressive disorder, bipolar disorder, insomnia, tremor, and other symptoms of Parkinson’s disease. Clinical studies of other compounds in this class, including brexanolone caprilcerbate, 3β-methoxypregnenolone, fasedienol, itruvone, C, and PH15, are currently ongoing. Ganaxolone is approved in several countries for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. Its potential use in the treatment of focal and generalized treatment-resistant epilepsy, as well as for the management of status epilepticus, is currently being evaluated in clinical trials. In summary, neurosteroids represent a promising new class of pharmacologically active compounds that are of considerable interest as therapeutic candidates with a broad range of potential clinical applications, including affective and anxiety disorders, sleep disturbances, neurodegenerative diseases, and various forms of epilepsy.

Authors

Institutions

Publication Details

Journal
Новые Санкт-Петербургские врачебные ведомости.
Published
2026-11-18
DOI
https://doi.org/10.24884/1609-2201-2026-105-3-56-65
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Neurosteroids for the pharmacotherapy of depression and other neuropsychiatric disorders: a review of clinical evidence

Sergey V. Okovityi, Приходько Вероника Александровна, A. V. Poberezhnaya, A. S. Drobyazko
Новые Санкт-Петербургские врачебные ведомости.
Treatment of Major Depression
article

Neurosteroids for the pharmacotherapy of depression and other neuropsychiatric disorders: a review of clinical evidence

Sergey V. Okovityi, Приходько Вероника Александровна, A. V. Poberezhnaya, A. S. Drobyazko
article en

Abstract

Postpartum (perinatal) depression (PPD) and treatment-resistant depression are prevalent affective disorders characterized by poor responsiveness to conventional antidepressant therapy. The family of neurosteroids (neuroactive steroids) comprises a number of endogenous molecules produced in the central and peripheral nervous systems, as well as their synthetic analogues, which are being investigated as promising therapeutic candidates. The primary mechanism of action of neurosteroids is based on the regulation of neuronal excitability through allosteric modulation of synaptic and extrasynaptic γ-aminobutyric acid receptors, predominantly the A subtype. Weak positive allosteric modulation of N-methyl-D-aspartate glutamate receptors and agonism at σ1-receptors further enhance the antidepressant effect and also account for the procognitive and neuroprotective properties observed in some neurosteroids. One of the most important advantages of neurosteroids as antidepressants is their rapid onset of action, which may be observed after the first administration. Zuranolone, available as oral capsules, has been approved in the United States and the European Union for the treatment of PPD in patients aged 18 years and older. In a number of clinical trials, zuranolone has demonstrated efficacy in major depressive disorder, bipolar disorder, insomnia, tremor, and other symptoms of Parkinson’s disease. Clinical studies of other compounds in this class, including brexanolone caprilcerbate, 3β-methoxypregnenolone, fasedienol, itruvone, C, and PH15, are currently ongoing. Ganaxolone is approved in several countries for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. Its potential use in the treatment of focal and generalized treatment-resistant epilepsy, as well as for the management of status epilepticus, is currently being evaluated in clinical trials. In summary, neurosteroids represent a promising new class of pharmacologically active compounds that are of considerable interest as therapeutic candidates with a broad range of potential clinical applications, including affective and anxiety disorders, sleep disturbances, neurodegenerative diseases, and various forms of epilepsy.

Новые Санкт-Петербургские врачебные ведомости.(3)
Saint - Petersburg State Chemical Pharmaceutical Academy (RU)
Good health and well-being
Treatment of Major Depression
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon